兴齐眼药（300573）公告，公司研发的盐酸利多卡因眼用凝胶于今日完成了"评价盐酸利多卡因眼用凝 胶用于眼表麻醉的有效性和安全性"的随机、双盲、阳性药平行对照、安慰剂平行对照、多中心临床试 验的首例受试者入组，正式进入Ⅲ期临床试验。盐酸利多卡因眼用凝胶适用于眼科操作中的眼表麻醉， 可延长药物与眼表面接触时间，改善麻醉效果。经查询国家药品监督管理局网站，仅有四川禾亿制药有 限公司的盐酸利多卡因眼用凝胶获批上市。本次公告的盐酸利多卡因眼用凝胶完成首例受试者入组，正 式进入Ⅲ期临床试验不会对公司近期业绩产生重大影响。 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-030 沈阳兴齐眼药股份有限公司 关于盐酸利多卡因眼用凝胶Ⅲ期临床试验首例受试者入组的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的盐酸利多卡因眼用 凝胶于今日完成了"评价盐酸利多卡因眼用凝胶用于眼表麻醉的有效性和安全性 的随机、双盲、阳性药平行对照、安慰剂平行对照、多中心临床试验"的首例受 试者入组，正式进入Ⅲ期临床试验。现将有关内容公告如下： 一、基本情况 药物名称：盐酸利多卡因眼用凝胶 注册分类：化学药品 3 类 二、临床试验相关情况 盐酸利多卡因是一种酰胺类局部麻醉药，被广泛用于浸润麻醉、硬膜外麻醉、 表面麻醉及神经传导阻滞。盐酸利多卡因眼用凝胶可延长药物与眼表面接触时间， 改善麻醉效果。 盐酸利多卡因眼用凝胶Ⅲ期临床试验为一项随机、双盲、阳性药平行对照、 安慰剂平行对照、多中心临床试验，以评价盐酸利多卡因眼用凝胶用于眼表麻醉 的有效性和安全性。 三、同类药品的情况 1 本次公告的盐酸利多卡因眼用凝胶是以盐酸利多卡因为活性成份的眼用 ...

Core Viewpoint - The A-share market has experienced significant structural changes over the past decade, with only a few industries surpassing their historical highs from 2015, while a select group of companies have demonstrated strong growth potential despite overall index stagnation [1][2]. Industry Performance - The top three performing industries from June 2015 to June 2025 are Food & Beverage, Home Appliances, and Banking, with most other industries failing to exceed their 2015 peak levels [1]. - Over the past ten years, more than 170 leading stocks in sectors such as Communication, Electronics, Biomedicine, and Machinery have achieved cumulative gains exceeding 300%, driven by macroeconomic transformation and industrial upgrades [2]. - The Food & Beverage sector has shown resilience due to its essential consumption characteristics, with leading companies in sub-sectors like liquor and snacks significantly outperforming major indices [4][6]. Notable Stocks - The top five stocks in the Food & Beverage sector over the past decade include: - Salted Fish (盐津铺子): 1,430.52% - Shanxi Fenjiu (山西汾酒): 863.43% - Kweichow Moutai (贵州茅台): 629.72% - Wanchen Group (万辰集团): 588.50% - Dongpeng Beverage (东鹏饮料): 572.38% [5][6]. - In the Home Appliances sector, Midea Group (美的集团) has led with a cumulative increase of 292.31% since 2015, while other notable companies have also seen significant gains [6]. Banking Sector Insights - The banking sector has outperformed many expectations, with the banking index reaching a historical high of 7,237.72 points, reflecting an 11.66% increase year-to-date and a 61.4% increase since last year [11]. - Notably, 39 out of 42 banking stocks have risen this year, with a significant portion of banks achieving over 200% growth since 2015 [11][12]. - The top-performing bank, China Merchants Bank, has seen a cumulative increase of 224.14%, while major state-owned banks have also doubled in value over the same period [12].

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 关于沈阳兴齐眼药股份有限公司 2025 年第一次临时股东大会的法律意见书 致：沈阳兴齐眼药股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称 "《公司法》"）以及中国证券监督管理委员会颁布的《上市公司股东会规则》 （以下简称"《股东会规则》"）的规定，北京市竞天公诚律师事务所（以下 简称"本所"）指派律师出席了沈阳兴齐眼药股份有限公司（以下简称"公 司"）2025年第一次临时股东大会（以下简称"本次股东大会"），并就本次 股东大会的有关事宜出具本法律意见书。 本所在此同意，公司可以将本法律意见书作为本次股东大会公告的法定文 件，随其他公告文件一并提交深圳证券交易所予以审核公告。 本所律师根据《股东会规则》第六条的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，对本次股东大会召集和召开的有关事实及公司 提供的文件进行了核查和验证，现出具法律意见如下： 一、本次股东大会的召集、召开程序 1、本次股东大 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2025-029 沈阳兴齐眼药股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开方式：本次会议以现场投票与网络投票相结合的方式召开。 2、现场会议时间：2025年6月13日（星期五）下午14:30。 3、网络投票时间：2025年6月13日，其中，通过深圳证券交易所交易系统进 行网络投票的具体时间为2025年6月13日9:15—9:25，9:30—11:30和13:00— 15:00；通过深圳证券交易所互联网投票系统进行网络投票的时间为2025年6月13 日9:15至15:00期间的任意时间。 4、现场会议召开地点：沈阳市浑南区泗水街68号，沈阳兴齐眼药股份有限 公司E1号楼，二楼多功能厅。 8、公司董事、监事、高级管理人员以及北京市竞天公诚律师事务所委派的 见证律师以现场的方式出席和列席了本次股东大会。 9、本次股东 ...

Core Viewpoint - The company Xingqi Eye Medicine, which previously dominated the market with its unique "myopia miracle drug" atropine sulfate eye drops, is now facing unprecedented competition as major players like Heng Rui Medicine and Zhao Ke Ophthalmology have received approval for similar products, threatening its market position [1][2]. Group 1: Market Competition - The approval of 0.01% atropine sulfate eye drops in March 2024 significantly boosted Xingqi's revenue, with eye drop sales soaring by 106% to 1.366 billion yuan, contributing over 10% to total revenue [2]. - Competitors such as Heng Rui Medicine and Zhao Ke Ophthalmology are advancing with their own products, with Heng Rui's subsidiary having a substantial sales force of 8,910 compared to Xingqi's 1,197, indicating a potential market share threat [2]. Group 2: Financial Performance - Xingqi's financial performance has been volatile, with net profit soaring by 208% in 2019 due to internal sales rights, but growth slowed to 12.55% in 2022 following new regulations on online prescription drug sales [3]. - The company reported a resurgence in growth of 44.54% in 2024 after the approval of its product, but acknowledged risks of slowing growth and declining market share as the product becomes more widely available [3]. Group 3: Cash Flow and Funding Challenges - The company has invested over 600 million yuan in R&D from 2022 to 2024, representing more than 12% of its revenue, but cash reserves have plummeted from 515 million yuan to 370 million yuan, with short-term loans increasing by 185% to 200 million yuan [4]. - To address its financial challenges, the founder Liu Jidong has opted to dilute his stake through a fundraising effort of 850 million yuan, reducing his ownership from 28.63% to 22.02%, marking the second significant financing attempt in four years [4].

Market Overview - As of 10:30 AM today, the Shanghai Composite Index stands at 3352.43 points, above the six-month moving average, with a change of 0.15% [1] - The total trading volume of A-shares today is 568.946 billion yuan [1] Stocks Performance - A total of 138 A-shares have surpassed the six-month moving average today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Dahongli (300865) with a deviation rate of 17.40%, closing at 27.74 yuan, up 19.98% [1] - Huaxi Biological (688363) with a deviation rate of 6.97%, closing at 54.41 yuan, up 7.87% [1] - *ST Chengchang (001270) with a deviation rate of 5.20%, closing at 36.55 yuan, up 5.00% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Zhejiang Shuwenhua (600633) with a deviation rate of 5.17%, closing at 13.62 yuan, up 5.66% [1] - Gehua Cable (600037) with a deviation rate of 4.76%, closing at 7.73 yuan, up 6.47% [1] - Stocks with smaller deviation rates that have just crossed the six-month line include Aotai Biological, Chitianhua, and Emei Mountain A [1]

沈阳兴齐眼药股份有限公司（以下简称"公司"）研发的 SQ-22031 滴眼液近 日获得了"评估 SQ-22031 滴眼液在健康受试者中单次/多次给药的安全性、耐受 性和药代动力学的单中心、随机、双盲、安慰剂对照的 I 期临床试验"临床研究 报告。根据《深圳证券交易所上市公司自律监管指引第 4 号——创业板行业信息 披露》的有关规定，现将主要内容公告如下： 一、基本情况 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-028 沈阳兴齐眼药股份有限公司 关于 SQ-22031 滴眼液取得 I 期临床研究报告的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本次公告的 SQ-22031 滴眼液适应症为神经营养性角膜炎。截至本公告披露 日，经查询国家药品监督管理局网站，尚无同品种药品批准上市。 1 药品名称：SQ-22031 滴眼液 剂型：滴眼剂 注册分类：治疗用生物制品 1 类 适应症：神经营养性角膜炎 临床试验批准通知书编号：2024LP01687、2024LP01688、2024LP01689、 2024LP01690 临床试验分期： ...

Core Viewpoint - Xingqi Eye Pharmaceutical is actively enhancing its technological capabilities and research and development (R&D) capacity through a planned stock issuance to raise up to 850 million yuan for R&D center construction and working capital supplementation [1][2][4]. Fundraising and Investment - The company plans to issue shares to specific investors, raising no more than 850 million yuan, with the net proceeds allocated entirely to the R&D center project and working capital [2][3]. - The stock issuance will not exceed 30% of the total share capital prior to the issuance, amounting to a maximum of 73.6 million shares [2]. - The R&D center aims to create a benchmark in the ophthalmology field, integrating smart laboratory matrices and collaborative innovation platforms, with a total investment of 984 million yuan [3]. Financial Performance - Xingqi Eye Pharmaceutical has achieved continuous growth in revenue and net profit for six consecutive years from 2019 to 2024 [1][6]. - In Q1 2025, the company reported a revenue of 536 million yuan, a year-on-year increase of 53.24%, and a net profit of 146 million yuan, soaring by 319.86% [6][7]. - The gross margin for Q1 2025 reached 80.16%, an increase of 4.06 percentage points year-on-year, while the net margin was 27.21%, up by 17.28 percentage points [7]. R&D Focus and Team - The company emphasizes R&D as the core driver of its development, holding 72 invention patents and 60 approved ophthalmic drug numbers, with 38 products included in the medical insurance directory [4][5]. - As of December 31, 2024, the company had 271 R&D personnel, accounting for 11.17% of the total workforce, with a significant portion holding master's degrees or higher [5]. Market Position and Strategy - Xingqi Eye Pharmaceutical is recognized as a leading domestic company in ophthalmic drug R&D, with a diverse product line covering various categories of eye medications [6]. - The company aims to enhance its competitive edge through differentiated innovation and to establish itself as an innovation-driven pharmaceutical enterprise [4].

消息面上，兴齐眼药发布的2025年度向特定对象发行股票预案显示，公司拟募集资金不超过(含)8.5亿元，扣除发行费用后的募集资金净额全部投资于研发中 心建设项目及补充流动资金，拟分别投入募资额6.5亿元、2亿元。 兴齐眼药表示，通过本次募投项目的实施，公司将打造国际视野的综合型研发总部，全面提升公司的研发实力，拓宽公司产品管线，优化公司现有产品结 构，突破技术壁垒，通过差异化创新形成竞争优势，为公司带来新的利润增长点。 这是兴齐眼药时隔四年再度进行定增募资。在2020年9月，兴齐眼药曾发布2020年度向特定对象发行A股股票预案，在最初的预案中，公司拟定增募资不超8 亿元。 值得一提的是，兴齐眼药此次定增募资的募投项目，与2020年的募投项目出现重合，均包含研发中心建设项目。 具体来看，此次预案显示，研发中心建设项目总投资金额9.84亿元，其中前次募集资金投入金额为2.08亿元，本次募集资金拟投入6.5亿元。目前本项目已启 动建设，计划于2027年底前建设完成。 抛出定增募资计划后，5月28日，兴齐眼药（300573）遭到了投资者"用脚投票"。 交易行情显示，5月28日，兴齐眼药低开2.5%，开盘后，公司股价不断 ...